Tina Cheng

Associate Professor

University of Calgary

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Tina Cheng is an Associate Professor at the University of Calgary, Canada. Her research predominantly focuses on immuno-oncology, particularly the efficacy of immune checkpoint inhibitors in treating melanoma and other malignancies. Recent publications highlight her investigations into clinical factors affecting long-term survival outcomes and the application of machine learning for predicting adverse events in patients undergoing immunotherapy.

Articles (7)

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Philippe L. Bedard

University Health Network

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tina Cheng

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Not Waiting to Progress; How the COVID-19 Pandemic Nudged Neoadjuvant Therapy for Stage III Locally Advanced Melanoma Patients

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials

Machine learning for prediction of cutaneous adverse events in patients receiving anti–PD-1 immunotherapy

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

Collaborators (1)

Philippe L. Bedard

Make your next move.